Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Summary by Ground News
Verve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.

2 Articles

STATSTAT
Center

FDA places clinical hold on Verve Therapeutics gene-editing treatment

The therapy, VERVE-101, uses a form of CRISPR to treat familial hypercholesterolemia, a relatively common form of high cholesterol.

·Boston, United States
Read Full Article
GEN - Genetic Engineering and Biotechnology News…GEN - Genetic Engineering and Biotechnology News…

FDA Places Clinical Hold on Verve's Cardio Base Editing Therapy

FDA places clinical hold on Verve Therapeutics' IND application for lead candidate VERVE-101 for Heterozygous Familial Hypercholesterolemia.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Monday, November 7, 2022.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

CRISPR icon

CRISPR

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal